The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK.
The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK.
Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s research and development base”.
Meanwhile, the UK’s Business Secretary, Vince Cable, balancing protectionist fears with an obligatory pro-market stance, took a more diplomatic perspective. Tentatively welcoming the deal, he explained that he had spoken to Pfizer CEO Ian Read to underline the importance of the continued provision of high-skilled jobs and long-term investment in UK R&D.
Frost & Sullivan’s Life Sciences Program Manager Ranjith Gopinathan, however, was optimistic that there’s a “strong possibility” Pfizer could move its base to the UK for tax saving purposes. (He does reiterate, however, the suggestion that “avoiding a higher tax in the US could be the major reason” behind the Pfizer move. [See more on this here.])
But U.S. law professor Erik Gordon, writing for the UK journal The Conversation, warns that the acquisition “is unlikely to produce another Lipitor-like success”. AZ’s potential “hit” cancer drugs are not at the stage Lipitor was when Pfizer got its hands on it, says Gordon. “They need more clinical work and they are riskier.”
Further, he adds, “If Pfizer is true to form, its culture will alienate the very people it needs to maximize the chances of getting AZ’s candidate drugs through the risks of approval and adoption. The result is unlikely to be positive for AZ shareholders who get Pfizer stock in an acquisition.”
Frost & Sullivan’s Gopinathan concedes that post-M&A integration has never been an easy task and that the merged company will still face stiff competition from drugmakers such as BMS and Roche. But, he adds, the move builds on the industry’s current, rapid consolidation strategy and could further help big pharma’s bargaining power with payers and government.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.